Most rare subtypes of cutaneous lymphoma display variable CD30 expression. Analysis of the German Cutaneous Lymphoma Network.

Most rare subtypes of cutaneous lymphoma display variable CD30 expression. Analysis of the German Cutaneous Lymphoma Network.
Br J Dermatol. 2021 Jan 22;:
Authors: Wehkamp U, Mitteldorf C, Stendel S, Stranzenbach R, Nicolay JP, Wobser M, Weichenthal M, Schneiderbauer R, Klemke CD, Hillen U, Kempf W, Assaf C
Abstract
CD30, also known as tumor necrosis factor receptor 8 (TNF-R 8), was primarily called Ki-1 and is a cell surface molecule which has first been described from a group of pathologists from Kiel in 1982.1 CD30 can be targeted with the drug brentuximab-vedotin (BV), which is approved for relapsed or refractory CD30+ cutaneous T-cell lymphoma (CTCL) including primary cutaneous anaplastic large cell lymphoma and CD30+ mycosis fungoides and Sézary syndrome.
PMID: 33480069 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - January 22, 2021 Category: Dermatology Authors: Wehkamp U, Mitteldorf C, Stendel S, Stranzenbach R, Nicolay JP, Wobser M, Weichenthal M, Schneiderbauer R, Klemke CD, Hillen U, Kempf W, Assaf C Tags: Br J Dermatol Source Type: research